Key result
High Age–D-dimer–Albumin score linked to ~58% higher all-cause mortality in CAD patients.
Why the study?
The Age-D-dimer-Albumin (ADA) score was originally designed to predict thrombotic risk, but its prognostic value for long-term mortality had not been systematically validated in coronary artery disease (CAD).
Does a high Age–D-dimer–Albumin (ADA) score predict higher rates of all-cause and cardiac mortality in patients with coronary artery disease?
Cohort (n=10,613)
No
Does a high Age–D-dimer–Albumin (ADA) score predict higher rates of all-cause and cardiac mortality in patients with coronary artery disease?
The Age–D-dimer–Albumin (ADA) score is independently associated with long-term all-cause and cardiac mortality in coronary artery disease patients, particularly within the acute coronary syndrome subgroup.
Answers are grounded in this paper and cite their sources.
ADA score may refine mortality risk stratification in CAD; extends biomarker scores but leaves open incremental value pending prospective validation.
Objectives The Age–D‐dimer–Albumin (ADA) score, which integrates age, coagulation activity, and nutritional status, was originally designed to predict thrombotic risk but has not been systematically validated in coronary artery disease (CAD). This study aimed to assess its prognostic value for long‐term mortality in a large prospective CAD cohort. Methods We conducted a secondary analysis of the PRACTICE cohort, including 10,613 CAD patients enrolled from 2016 to 2021. The ADA score was calculated as −0.5 × Alb (g/L) + 0.4 × D‐dimer/100 (ng/mL) + 0.3 × age (years). Receiver operating characteristic analysis identified an optimal cutoff of −13.5, and patients were categorized into low‐ADA (< −13.5, n = 6733) and high‐ADA (≥ −13.5, n = 3880) groups. The primary endpoints were all‐cause mortality (ACM) and cardiac mortality (CM). Results During a median follow‐up of 24 months, 340 ACM and 258 CM events occurred. High‐ADA patients showed significantly higher risks of ACM (6.0% vs. 1.6%) and CM (4.5% vs. 1.2%) compared with low‐ADA patients (both p < 0.001). After adjustment for conventional risk factors, ADA remained independently associated with ACM (HR 1.58, 95% CI 1.13–2.21; p = 0.008) and CM (HR 1.62, 95% CI 1.10–2.38; p = 0.015) but not with ischemic events (MACEs or MACCEs). Restricted cubic spline (RCS) analysis demonstrated an approximately linear positive dose–response relationship between the ADA score and the risks of ACM and CM. Subgroup analysis revealed a distinct ACS subtype‐specific prognostic value of the ADA score, with its independent predictive efficacy for long‐term mortality being significantly better in the ACS subgroup than in the stable coronary artery disease (SCAD) subgroup. ROC curve comparison between the ADA score and its individual components demonstrated significantly better prognostic performance only over Alb, with no significant differences observed for age or D‐dimer. Conclusions The ADA score is independently associated with long‐term ACM and CM in CAD patients, with an approximately linear positive dose–response relationship by restricted cubic spline analysis. Its prognostic efficacy is significantly superior in the ACS subgroup than in the SCAD subgroup, serving as a simple, accessible tool for risk stratification. Further multicenter studies are needed to validate its clinical utility. Trial Registration: ClinicalTrials.gov identifier: NCT05174143
No takes yet. Share an insight, caveat, or question.
Bai et al. (2026) conducted a cohort in Coronary artery disease (n=10,613). High Age–D-dimer–Albumin (ADA) score (≥ -13.5) vs. Low Age–D-dimer–Albumin (ADA) score (< -13.5) was evaluated on All-cause mortality (ACM) and cardiac mortality (CM) (HR 1.58, 95% CI 1.13-2.21, p=0.008). A high Age–D-dimer–Albumin score (≥-13.5) was independently associated with higher all-cause (HR 1.58; 95% CI 1.13-2.21) and cardiac mortality (HR 1.62; 95% CI 1.10-2.38) in CAD patients.
Synapse has enriched 10 related papers. Consider them for comparative context: